Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10161)	5/23/1999 3:16:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

You stated,>>>>>>>It leaves us waiting to see what the data reveal. IMO however, the SOC for severe meningococcal sepsis has not changed in the U.K. If it had they would be falling all over themselves to tell everyone how to save kids.<<<<<<<<<<< Soooo, if you take away the SOC issue where does that leave you? Why would you have to wait on Xoma to provide any other information? If Neuprex was dismal on efficacy why would the trial been allowed to be expanded to UK and extended N wise? If Xoma didn't reach the mortality number when at almost 400 then WHY? What was the FDA consulted about ending of the trial and why might that be important? My opinion only but I still think zero mortality in treatment group unless you had some kids entered in treatment group severely obese and with fatty coronary artery disease.